Cargando…
Response: Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors (Diabetes Metab J 2019;43:158–73)
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Korean Diabetes Association
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6581550/ https://www.ncbi.nlm.nih.gov/pubmed/31210038 http://dx.doi.org/10.4093/dmj.2018.0106 |
| _version_ | 1783428180012433408 |
|---|---|
| author | Lee, Ji-Yeon Kang, Eun Seok |
| author_facet | Lee, Ji-Yeon Kang, Eun Seok |
| author_sort | Lee, Ji-Yeon |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6581550 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Korean Diabetes Association |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-65815502019-06-24 Response: Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors (Diabetes Metab J 2019;43:158–73) Lee, Ji-Yeon Kang, Eun Seok Diabetes Metab J Response Korean Diabetes Association 2019-06 2019-06-13 /pmc/articles/PMC6581550/ /pubmed/31210038 http://dx.doi.org/10.4093/dmj.2018.0106 Text en Copyright © 2019 Korean Diabetes Association http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Response Lee, Ji-Yeon Kang, Eun Seok Response: Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors (Diabetes Metab J 2019;43:158–73) |
| title | Response: Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors (Diabetes Metab J 2019;43:158–73) |
| title_full | Response: Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors (Diabetes Metab J 2019;43:158–73) |
| title_fullStr | Response: Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors (Diabetes Metab J 2019;43:158–73) |
| title_full_unstemmed | Response: Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors (Diabetes Metab J 2019;43:158–73) |
| title_short | Response: Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors (Diabetes Metab J 2019;43:158–73) |
| title_sort | response: predictors of the therapeutic efficacy and consideration of the best combination therapy of sodium-glucose co-transporter 2 inhibitors (diabetes metab j 2019;43:158–73) |
| topic | Response |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6581550/ https://www.ncbi.nlm.nih.gov/pubmed/31210038 http://dx.doi.org/10.4093/dmj.2018.0106 |
| work_keys_str_mv | AT leejiyeon responsepredictorsofthetherapeuticefficacyandconsiderationofthebestcombinationtherapyofsodiumglucosecotransporter2inhibitorsdiabetesmetabj20194315873 AT kangeunseok responsepredictorsofthetherapeuticefficacyandconsiderationofthebestcombinationtherapyofsodiumglucosecotransporter2inhibitorsdiabetesmetabj20194315873 |